NASDAQ:MBIO
Mustang Bio Inc Stock News
$0.335
+0.0231 (+7.40%)
At Close: May 20, 2024
Caribou Charges Ahead on Study Results
03:07pm, Tuesday, 17'th May 2022
Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that also rose after investors got a look at the prese
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
08:05pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
Data from two programs selected for oral presentations at the upcoming American Society of Gene & Cell Therapy 25th Annual Meeting and the European Hematology Association 2022 Hybrid Congress this qua
Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations
12:30pm, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
Fred Hutch’s Dr. Mazyar Shadman to present data on Mustang’s autologous CAR T-cell therapy for the treatment of B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia Fred Hutch’s Dr. Maz
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
08:00am, Monday, 04'th Apr 2022
WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs i
Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
08:05pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
WORCESTER, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroug
Mustang Bio Inc. (NASDAQ: MBIO) Rose 8.86% From Its 52-Week Low, But YTD Numbers Fell -52.17%. Here’s What You Need To Know At This Time
01:00pm, Saturday, 12'th Mar 2022 Marketing Sentinel
During the last session, Mustang Bio Inc. (NASDAQ:MBIO)’s traded shares were 0.52 million, with the beta value of the company hitting 1.69. At the end of the trading day, the stock’s price was $0.79, reflecting an intraday loss of -3.79% or -$0.04. The 52-week high for the MBIO share is $4.06, that puts it down … Mustang Bio Inc. (NASDAQ: MBIO) Rose 8.86% From Its 52-Week Low, But YTD Numbers Fell -52.17%. Here’s What You Need To Know At This Time Read More »
Captivating Stock: Orchard Therapeutics plc (NASDAQ:ORTX), Mustang Bio, Inc. (NASDAQ:MBIO)
06:53am, Friday, 11'th Mar 2022 Stock Equity
Orchard Therapeutics plc (NASDAQ:ORTX) with the stream of -1.81% also noticed, India Mustang Bio, Inc. (NASDAQ:MBIO) encountered a rapid change of -6.41% in the last hour of Thursday’s trading session. … The post Captivating Stock: Orchard Therapeutics plc (NASDAQ:ORTX), Mustang Bio, Inc. (NASDAQ:MBIO) appeared first on Stocks Equity .
Mustang Bio to Participate in Three March 2022 Investor Conferences
01:30pm, Thursday, 10'th Mar 2022 GlobeNewswire Inc.
WORCHESTER, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrou
Mustang Bio to Participate in Three March 2022 Investor Conferences
08:30am, Thursday, 10'th Mar 2022
WORCHESTER, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs
WORCESTER, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO ), a clinical-stage biopharmaceutical company focused on translating today''s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that an abstract reporting on Phase 1 trials being conducted at the University of Alabama at Birmingham (UAB) and City of Hope of Mustang Bio''s exclusively licensed oncolytic viral and CAR T-cell therapies for the treatment of patients with glioblastoma (GBM), has been selected as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8 – 13, 2022, in New Orleans, Louisiana. The abstract will also be published in the online Proceedings of the AACR . Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, "We look forward to the upcoming data to be presented by City of Hope''s Dr.
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
12:30pm, Tuesday, 15'th Feb 2022 GlobeNewswire Inc.
WORCESTER, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrough
Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards
01:30pm, Tuesday, 08'th Feb 2022 GlobeNewswire Inc.
WORCESTER, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrough
Remarkable Stock Buzz: Fluidigm Corporation (NASDAQ:FLDM), Mustang Bio, Inc. (NASDAQ:MBIO)
12:30am, Tuesday, 08'th Feb 2022 Stock Equity
Fluidigm Corporation (NASDAQ:FLDM) with the stream of 4.85% also noticed, India Mustang Bio, Inc. (NASDAQ:MBIO) encountered a rapid change of 0.00% in the last hour of Mondays trading session. Fluidigm The post Remarkable Stock Buzz: Fluidigm Corporation (NASDAQ:FLDM), Mustang Bio, Inc. (NASDAQ:MBIO) appeared first on Stocks Equity .
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
12:46pm, Tuesday, 25'th Jan 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate
Pfizer, Inc. (NYSE: PFE) and BioNT